Triamcinolone

Selected 0.1% skin cream/ointment relieve inflammatory and itchy manifestations of corticosteroid-responsive dermatoses. Sun dental paste is adjunctive temporary relief for oral inflammatory lesions and traumatic ulcerative lesions; skin products must not replace it. OTC Nasacort temporarily relieves allergic nasal congestion, rhinorrhea, sneezing and itchy nose at age ≥ 2; it is not for the common cold.

Amneal 40 mg/mL suspension: IM treatment when oral therapy is not feasible for listed severe allergic, inflammatory, rheumatic, endocrine, hematologic, renal and other disorders; IA/soft-tissue use is short-term adjunctive treatment for acute gouty arthritis, bursitis, nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis and osteoarthritis synovitis. Zilretta is IA management of knee osteoarthritis pain; repeat-dose safety/efficacy is not demonstrated, and shoulder/hip OA is not evaluated. This overview is not a disease-specific systemic steroid protocol.

This reference covers six selected U.S. acetonide labels. Other skin strengths/vehicles, 10/80 mg/mL injections, dedicated ophthalmic formulations and triamcinolone hexacetonide need their own labels and specialist directions. The selected 40 mg/mL suspension is IM/IA only, not IV, intradermal or an ophthalmic substitute. Zilretta is not substitutable with other triamcinolone injections.

Shake well before every use. Prime new bottle and re-prime after > 2 weeks unused per enclosed insert; read spray/cleaning directions. Spray while sniffing gently; do not spray into eyes/mouth or share bottle. No doubled missed dose.

These selected doses require trained aseptic administration, individual indication/risk assessment and the exact product. They are not repeat-injection schedules.

No fixed renal/hepatic dose algorithm is provided for these selected forms. Systemic steroids require caution with renal insufficiency, HF/hypertension, electrolyte disturbance and cirrhosis (enhanced effects). Individualize dose/duration; prolonged systemic treatment needs gradual clinician-directed withdrawal and stress-dose planning, not an arbitrary universal taper. Amneal suspension: shake, inspect for clumping/agglomeration (discard if present), inject promptly after withdrawal. Zilretta: only supplied diluent, strict asepsis, prompt injection; prepared vial may be held up to 4 hours ambient and gently resuspended before withdrawal.

All selected products preclude hypersensitivity to their ingredients; Zilretta also specifies corticosteroid hypersensitivity. Dental paste is additionally contraindicated with fungal, viral or bacterial infection of the mouth/throat. OTC Nasacort: do not use below age 2. Amneal IM corticosteroid use is contraindicated in idiopathic thrombocytopenic purpura; live vaccines are contraindicated during immunosuppressive doses. Infection-site injection and unapproved routes remain important restrictions even when listed in warnings rather than section 4.

These selected current U.S. labels have no boxed warning. The selected immediate-release injection prominently warns about serious neurologic events with epidural administration; absence of a box does not establish that route as safe or approved.

Skin/dental effects include burning, itching, dryness, contact dermatitis, infection and tissue atrophy; skin effects also include striae, folliculitis, pigment changes and acne-like eruptions. Injection can cause post-injection flare, joint/tendon injury and systemic steroid reactions above. Zilretta trial reactions include sinusitis, cough and contusions. Nasal labeling highlights nosebleeds, vision change and growth risk without assigning trial incidence. Excess local or injected steroid exposure can cause systemic toxicity; contact medical care/Poison Help (U.S. 1-800-222-1222) for overdose. Chronic excess needs a supervised reduction plan.

Selected injection labels describe systemic corticosteroid interactions; topical/OTC nasal labels do not provide an equivalent full interaction table. Review all steroid routes together.

Skin/dental labels lack adequate pregnancy studies and advise use only when benefit justifies risk; avoid extensive/prolonged skin exposure. Injectable pregnancy data are limited and animal studies identify developmental risks; infants exposed to systemic maternal steroids need assessment for adrenal effects. Zilretta has no direct human pregnancy data, and other-route evidence has limited applicability. Milk/infant effects are incompletely characterized for local forms; systemic steroids enter milk. Discuss route-specific benefits/risks. OTC Nasacort directs pregnant/breastfeeding users to a health professional.

Skin treatment in children uses the least effective amount and monitors growth/systemic effects; no universal minimum age is specified. Dental-paste pediatric safety/efficacy is unknown. Nasacort is for age ≥ 2 with age-specific dosing and review beyond 2 months/year. Selected IM/IA steroid pediatric regimens are disease-specific; label class divided-dose ranges are not converted here into a depot-injection schedule. Zilretta pediatric safety/effectiveness is not established. Older adults may be more sensitive despite no overall injection-trial differences; dental-paste trials had insufficient older participants.

The selected skin, dental and nasal labels give no fixed renal/hepatic adjustment. Absorbed corticosteroids are primarily hepatically metabolized with renal/biliary excretion. Injection requires attention to renal fluid/electrolyte effects, BP/edema and enhanced effects in cirrhosis; individualize rather than applying an unvalidated percentage reduction.

Triamcinolone acetonide activates glucocorticoid-receptor pathways with anti-inflammatory/immunomodulating effects; topical labels also describe antipruritic and vasoconstrictive effects. Exact topical anti-inflammatory mechanisms are incompletely established. Zilretta’s PLGA microspheres provide prolonged local release.

Skin / oral mucosa

Absorption varies with vehicle, barrier damage/inflammation, area, duration and skin occlusion. No universal plasma half-life predicts safety for every local product.

Immediate-release IM suspension

Effect can last weeks. Studied single IM 60–100 mg caused adrenal suppression within 24–48 hours, usually recovering in 30–40 days; this is not a repeat-dose instruction.

Zilretta IA

Systemically absorbed despite local delivery; study cortisol suppression began within 12–24 hours and normalized within 30–42 days.

Formulation distinction

Extended-release IA exposure differs from conventional IA suspension; label expressly prohibits substitution. Adrenal effects can outlast symptom benefit.

• Skin/dental: response, irritation, infection and atrophy; evaluate HPA suppression when large/prolonged/occluded exposure warrants (urinary free cortisol or ACTH stimulation per label).
• Nasal: response by 1 week, nosebleeds, vision and child growth/use duration; review all steroid products.
• Injection: infection/septic joint, glucose, BP/edema, electrolytes, mood, bone/muscle and ocular effects according to exposure/risk. Amneal recommends intraocular-pressure monitoring if systemic therapy continues > 6 weeks.
• Before prolonged immunosuppression assess hepatitis B and relevant latent infections per current Amneal warnings; arrange withdrawal and stress-dose plans.

Use the exact form only for its prescribed route/condition. Do not cover skin without instructions or rub dental paste in. Read Nasacort insert, avoid sharing and do not double a missed dose. Inform clinicians of all steroid use and injections; do not abruptly stop prolonged systemic therapy. Seek urgent care for airway swelling, severe infection, post-injection hot/swollen painful joint with fever, marked mood disturbance or serious eye symptoms. Avoid chickenpox/measles exposure during systemic immunosuppression and seek prompt advice if exposed.

Encube triamcinolone acetonide 0.1% skin cream contains 1 mg/g. Example 15 g tube NDC 21922-062-04; also 30/80 g tubes and 454 g jar. Skin cream is not dental paste, nasal spray or injection.

Skin cream: 15–30°C, avoid excess heat and protect from freezing. Selected skin ointment: 20–25°C. Dental paste: tightly closed at 20–25°C. Nasacort: 20–25°C; keep package/insert. Amneal 40 mg/mL: 20–25°C in carton, upright, do not refrigerate; allowed excursions 15–30°C, avoid temperatures below 20°C as label directs; discard single-dose remainder, opened multidose maximum 28 days at 15–25°C per label. Zilretta unopened kit: 2–8°C; if refrigeration unavailable, sealed kit ≤ 25°C up to 3 weeks then discard; no freezing or > 25°C exposure. Prepared-vial hold is separate: up to 4 hours ambient, resuspend. Keep securely away from children.